The global liver cancer diagnostics market size was valued at USD 13.65 billion in 2025 and is projected to grow from USD 14.66 billion in 2026 to USD 25.95 billion by 2034, registering a CAGR of 7.4% during the forecast period from 2026 to 2034. North America dominated the liver cancer diagnostics market with a market share of 41.86% in 2025.

The liver cancer diagnostics market focuses on medical tests and technologies used to detect liver cancer, assess its stage, and monitor disease progression. Diagnostic methods include laboratory tests, imaging, endoscopy, and biopsy. These methods help healthcare professionals identify tumors, assess the extent of the disease, and make informed decisions about treatment.

The market is growing as healthcare providers focus on early detection and regular screening of high-risk populations. Increasing adoption of non-invasive diagnostic methods, rising cases of metabolic disorders, and improvements in medical testing are supporting demand for liver cancer diagnostic services.

Market Drivers

Need for Staging Before Treatment and Continuous Disease Monitoring

The need for accurate diagnosis before treatment is a major factor driving the liver cancer diagnostics market. Healthcare professionals use CT scans, MRI, ultrasound, and alpha-fetoprotein (AFP) tests to assess tumors and determine the stage of the disease. These results help doctors select suitable treatment options, including surgery, ablation, and systemic therapy. This creates demand for diagnostic tests across hospitals and cancer treatment centers.

Continuous monitoring also supports market growth because patients require follow-up tests to assess treatment response, identify recurrence, and track disease progression. Regular imaging and laboratory testing increase the use of diagnostic services throughout the patient's care journey. This ongoing demand supports diagnostic laboratories and medical technology providers.

Market Restraints

Inconsistent Screening Guidelines and Shortage of Specialized Experts

Differences in screening practices across countries limit the widespread adoption of liver cancer diagnostics. Some healthcare systems follow structured surveillance programs for high-risk individuals, while others lack consistent screening protocols. This creates uneven demand for diagnostic services and makes it difficult to expand screening coverage across regions.

The shortage of trained radiologists and liver disease specialists is another challenge. Accurate interpretation of CT and MRI scans requires specialized expertise, and limited staff can reduce diagnostic capacity, particularly in areas with fewer healthcare resources. These barriers can delay diagnosis and restrict the effective use of available diagnostic equipment.

Market Opportunities

Expansion of Screening Programs and Affordable Diagnostic Solutions

The expansion of screening among high-risk populations creates new opportunities in the liver cancer diagnostics market. Individuals with cirrhosis, chronic hepatitis, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease may require regular monitoring. Hospitals, diagnostic laboratories, and testing providers can benefit from the growing demand for accessible screening solutions.

The need for affordable diagnostic methods also creates revenue opportunities for market players. Lower-cost blood tests and accessible imaging solutions can improve testing access in regions where expensive procedures limit adoption. Companies that develop scalable diagnostic tools can reach more patients and expand their presence in underserved markets.

Market Segmentation

The liver cancer diagnostics market is segmented by test type and end use.

By test type, the market includes laboratory tests, imaging, endoscopy, biopsy, and other diagnostic methods. The laboratory tests segment accounted for 41.54% of the market in 2025 and is projected to grow at a CAGR of 8.1% during the forecast period. These tests support routine diagnosis and monitoring, while automated laboratory systems help healthcare facilities process larger numbers of samples. The imaging segment is projected to grow at a CAGR of 7.9%, supported by its role in tumor detection, localization, and staging.

By end use, the market includes hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and contract research organization (CRO) laboratories. Hospitals and diagnostic laboratories accounted for the largest share of 51.43% in 2025 because they provide essential testing, imaging, and pathology services. Pharmaceutical and CRO laboratories are expected to grow at a CAGR of 9.52%, supported by their role in research and diagnostic development.

Regional Insights

North America dominated the liver cancer diagnostics market in 2025, accounting for 41.86% of the global market. Strong healthcare infrastructure, broad insurance coverage, and access to advanced diagnostic services support the region's leading position. The rising burden of liver cancer in the United States also increases demand for early detection and follow-up testing.

Europe is expected to be the fastest-growing region, with a projected CAGR of 9.54% during the forecast period. Investment in biomarker research, academic hospitals, and advanced diagnostic technologies supports regional growth. The adoption of innovative testing methods and improvements in clinical diagnostic practices are also expected to increase demand.

Asia-Pacific offers growth potential as healthcare infrastructure expands and demand for cancer diagnosis increases. Latin America and the Middle East and Africa also present opportunities as healthcare providers work to improve access to diagnostic services and affordable testing solutions.

Key Players Analysis

Key companies operating in the liver cancer diagnostics market include:

• Abbott Laboratories

• Hoffmann-La Roche Ltd.

• Qiagen N.V.

• Thermo Fisher Scientific

• Siemens Healthineers

• Becton Dickinson and Company

• Illumina Inc.

• Epigenomics AG

• Koninklijke Philips N.V.

• Fujifilm Medical Systems U.S.A., Inc.

• Danaher Corporation

• Agilent Technologies

• Sysmex Corporation

• Hologic Inc.

• Guardant Health

These companies compete through diagnostic product development, technology improvements, and efforts to increase testing accuracy and accessibility. Established companies benefit from broad product portfolios and distribution networks, while emerging firms focus on technologies such as liquid biopsy and AI-based imaging.

Conclusion

The liver cancer diagnostics market is expected to expand as healthcare providers increase screening, improve diagnostic accuracy, and monitor patients more regularly. Demand for laboratory tests, advanced imaging, and affordable screening solutions will create opportunities for diagnostic companies and healthcare providers. However, inconsistent screening practices and shortages of specialized professionals remain important challenges. Wider access to affordable testing and improvements in diagnostic technology will support the market's long-term development.

Source: Straits Research – Liver Cancer Diagnostics Market

About Us

Straits Research is a market intelligence and consulting organization that provides industry insights, market research reports, and strategic business analysis across various sectors. Its research helps businesses understand market trends, evaluate growth opportunities, and make informed decisions.

Contact Us

Email: [email protected]

U.S.: +1 646 905 0080

U.K.: +44 203 695 0070